New therapeutic approaches are currently being developed with the aim of blocking the production of SOD-1 mutated forms, a strategy that could likely ameliorate the clinical course of patients affected by the familial form of ALS. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.